Neuromuscular

17-21 of 21

• 

  RestartResume

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  RestartResume

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  MinuteCE®

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  RestartResume

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  MinuteCE®

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  RestartResume

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  MinuteCE®

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

• 

  RestartResume

  Novel Mechanisms of Action: FcRn Inhibitors

  RestartResume

  Novel Mechanisms of Action: FcRn Inhibitors

  MinuteCE®

  Novel Mechanisms of Action: FcRn Inhibitors

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  RestartResume

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  MinuteCE®

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit